Navigation Links
Niiki Pharma Forms Scientific Advisory Board with Leading U.S. Oncologists
Date:2/1/2012

HOBOKEN, N.J. and PHILADELPHIA, Feb. 1, 2012 /PRNewswire/ -- Niiki Pharma Inc. announced today the formation of its Scientific Advisory Board. Daniel Haller M.D. will chair the advisory board, and will be joined by Lee Ellis M.D. and Matt Kulke M.D. The Board will provide clinical and strategic guidance to the company for its two first-in-class clinical stage anti-cancer compounds, NKP-1339 and NKP-2235. As the pipeline continues to mature, the Advisory Board will be expanded.

The initial focus of the board will be Niiki Pharma's promising lead compound, NKP-1339. NKP-1339, a small molecule that down-regulates GRP78, has recently completed the dose-escalation portion of its Phase I clinical trial.

"Although we have an increasing number of drugs for a diverse spectrum of diseases, new drugs that may have higher benefit and lower toxicity for our patients are always needed," said Dr. Haller. "This Board welcomes the opportunity to participate in the development of these agents."

Dr. Daniel Haller is internationally renowned in the field of oncology. He is currently Professor of Medicine in the Department of Medicine at the Abramson Cancer Center at the University of Pennsylvania. In addition to his leadership in clinical research throughout the NCI and cancer cooperative group system, Dr. Haller is currently co-chair of the NCI Gastrointestinal Intergroup. He served as Editor-in-Chief of the Journal of Clinical Oncology, the official journal of the American Society of Clinical Oncology (ASCO), was the Associate Editor of the Annals of Internal Medicine and was Editor-in-Chief of PDQ, the National Cancer Institute's cancer information database.

Dr. Lee Ellis is an internationally recognized surgical oncologist, researcher, and leader in the field of translational oncology. He holds several positions at University of Texas MD Anderson Cancer Center, including Professor of Surgery and Cancer Biology; Director, Metastasis Research Center; Director, Colorectal Cancer Translational Research Program; and Chair, Ad Interim, Department of Cancer Biology. Dr. Ellis is vice-chair of the NCI Colon Cancer Task Force and serves on 8 editorial boards, including Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research. Dr. Ellis has served in leadership roles in major cancer societies including ASCO, American Association for Cancer Research, and the Society for Surgical Oncology.

Dr. Matthew Kulke is a world expert in neuroendocrine (NET) tumors. He is Associate Professor of Medicine at Harvard Medical School and Dana-Farber Cancer Institute, where he leads the Carcinoid and Neuroendocrine Tumor Program. He has a leadership role in the Cancer and Leukemia Group B (CALGB) Gastrointestinal Cancer Committee, chairs the NCI NET Task Force and NCCN NET guidelines committees, and serves on the executive committee of the North American Neuroendocrine Tumor Society. Dr. Kulke has chaired multiple global pivotal studies exploring new therapies for NET.

About NKP-1339
NKP-1339 is a first-in-class small molecule anti-cancer compound that down-regulates GRP78, a known tumor survival and anti-apoptosis factor. In preclinical studies, NKP-1339 has demonstrated activity against multiple tumor types. In the Phase I trial, antitumor activity was seen against multiple cancers, including NET.

About NKP-2235
NKP-2235 is a first-in-class orally available small molecule that targets the endoplasmic reticulum with a unique pattern of cytotoxicity. NKP-2235 IND has been cleared and a Phase I trial will be initiated shortly.

NKP-1339 and NKP-2235 were discovered by Professor Bernhard Keppler, University of Vienna, Austria.

About Niiki Pharma Inc.
Niiki Pharma (www.niikipharma.com) is a development focused oncology company specializing in first-in-class cancer treatments directed at novel tumor targets and related companion diagnostics.


'/>"/>
SOURCE Niiki Pharma Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Novel First-in-Class Anti-Cancer Agent in Development by Niiki Pharma Shows Promising Phase I Results
2. Niiki Pharma Announces Positive Interim Data from Ongoing Clinical Trial of Novel Anti-Cancer Agent NKP-1339
3. Niiki Pharma Reports on Synergistic Activity of Novel Anti-Cancer Agent NKP-1339 with Other Anti-Cancer Agents
4. Niiki Pharma Announces the Completion of Phase I Dose Escalation for First-in-Man Anti-Cancer Agent NKP-1339
5. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  In a startling report released ... failing their residents by lacking a comprehensive, proven plan to eliminate ... a definitive ranking of how states are tackling the worst drug ... only four states – Kentucky , ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... offering. The current unmet ... for MedImmune to enter. The US ageing population creates a ... considerable growth for effective anti-influenza medications. The introduction of a ... development is still in its infancy. Key ...
Breaking Medicine Technology:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... for mental health professionals, announced today its affiliation with Tennessee Counseling Association. ... solutions to the network of the Tennessee Counseling Association, adding exclusive benefits and ...
(Date:6/27/2016)... ... 2016 , ... A revolution is underway. Brooklyn-based company, ... for the millions of people who require these medical transport services annually. ... the use of technology. Now, SmartEMS has put forth an industry-changing app that ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in ... ways they remain in the eye of the beholder, according to experts who offered ... The American Journal of Managed Care. For the full issue, click here . ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer ... through a fitness app. The fitness app plans to fix the two major problems leading ... a one size fits all type program , They don’t eliminate all the ...
Breaking Medicine News(10 mins):